December 2, 2025
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read More
November 7, 2025
GDFATHER-01 Trial Long Term Follow-Up: GDF-15 Neutralization Combined With Nivolumab Can Enable Deep, Long-Term Remission In Heavily Pretreated, Anti-PD1/-L1 Relapsed/ Refractory Major Solid Tumor Types
Ignacio Melero Bermejo, María de Miguel Luken, Elena Garralda Cabanas, Guillermo de...
Read More
October 20, 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in...
Read More
October 17, 2025
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase...
Read More
September 30, 2025
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read More
September 22, 2025
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial...
Read More